Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Net Income

Bottom-line profit after all expenses, interest, and taxes.

Cardiff Oncology, Inc.NASDAQ: CRDF

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$12.35M, compared with -$13.43M a year earlier. Trailing-twelve-month net income was -$44.76M.

Context

  • Net income amounted to 7732.0% of revenue in FY2025, up 1080.4 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$39.95M (+12.9%) for the fiscal year ending Dec 2026, a step up from the -0.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.35M-71.1% QoQ
Last fiscal yearDec 2025
-$45.85M-0.9% YoY
LTMMar 2026
-$44.76M+8.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.1%+34.6%+26.5 pp
1 year-0.9%+12.9%+13.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(45.85M) USD
Year-over-year change
-0.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.4% is the 3rd highest of 9, against a peer median of -8.4%.
  • Net income amounts to 8526.1% of revenue for CRDF, versus a peer median of 1764.5%.
CRDF Competitors
Net Income for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$29.44M USD+1.2%—929.1%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$40.19M USD+21.6%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$44.76M USD+8.4%—8526.1%
IPHAInnate Pharma S.A.FY2025-€49.18M EUR+0.6%—1764.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$68.36M USD-31.7%—3832.0%
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.06M CHF-17.4%——
FBRXForte Biosciences, Inc.LTM Mar 2026-$75.86M USD-73.5%——
PEPGPepGen Inc.LTM Mar 2026-$77.22M USD+24.4%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.53M USD-68.1%——
Peer median (excluding CRDF) —-8.4%—1764.5%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue359K386K488K683K593K
Cost of Revenue00000
Gross Profit359K386K488K683K593K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development17.38M27.11M32.86M36.85M35.33M
Selling, General & Admin11.84M13.18M13.04M12.48M14.22M
Operating Expenses29.21M40.29M45.9M49.33M49.55M
Depreciation & Amortization451K236K398K404K904K
EBITDA(27.84M)(38.47M)(41.04M)(45.03M)(44.95M)
EBITDA Margin-7754.9%-9965.8%-8410.5%-6592.5%-7579.6%
Operating Income(28.86M)(39.9M)(45.41M)(48.65M)(48.96M)
Operating Margin-8037.6%-10337.3%-9305.7%-7123.1%-8256.3%
Interest Income264K1.58M4.07M3.26M3.1M
Interest Expense00000
Other Income / Expenses564K1.2M3.97M3.22M3.11M
Income Before Tax(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Pre-Tax Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
Income Tax Expense00000
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Net Margin-7880.5%-10026.9%-8492.0%-6651.7%-7732.0%
EPS (Basic)(0.73)(0.89)(0.93)(0.95)(0.69)
EPS (Diluted)(0.73)(0.89)(0.93)(0.95)(0.69)
Weighted Avg Shares39.03M43.6M44.68M47.65M66.84M
Weighted Avg Shares (Diluted)39.03M43.6M44.68M47.65M66.84M

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.